{"id":"jnj-90301900-nbtxr3","safety":{"commonSideEffects":[{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Dermatitis"},{"rate":null,"effect":"Dysphagia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Radiation-related toxicity (enhanced)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"NBTXR3 consists of hafnium oxide nanoparticles that accumulate preferentially in tumor tissue. When exposed to ionizing radiation, these nanoparticles amplify the local dose deposition and generate secondary electrons that increase DNA damage and cell death in cancer cells. This mechanism allows for improved therapeutic efficacy of standard radiotherapy regimens.","oneSentence":"NBTXR3 is a nanoparticle hafnium oxide that concentrates radiation dose within tumor cells, enhancing the cytotoxic effects of radiotherapy.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:47.084Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Locally advanced squamous cell carcinoma of the head and neck (in combination with radiotherapy)"},{"name":"Soft tissue sarcoma (in combination with radiotherapy)"}]},"trialDetails":[{"nctId":"NCT04892173","phase":"PHASE3","title":"JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC","status":"RECRUITING","sponsor":"Johnson & Johnson Enterprise Innovation Inc.","startDate":"2021-12-10","conditions":"Locally Advanced Head and Neck Squamous Cell Carcinoma, Aged","enrollment":500},{"nctId":"NCT07219212","phase":"PHASE1","title":"A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Johnson & Johnson Enterprise Innovation Inc.","startDate":"2026-01-26","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":45,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Functionalized hafnium oxide nanoparticles","NBTXR3"],"phase":"phase_3","status":"active","brandName":"JNJ-90301900 (NBTXR3)","genericName":"JNJ-90301900 (NBTXR3)","companyName":"Johnson & Johnson Enterprise Innovation Inc.","companyId":"johnson-johnson-enterprise-innovation-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NBTXR3 is a nanoparticle hafnium oxide that concentrates radiation dose within tumor cells, enhancing the cytotoxic effects of radiotherapy. Used for Locally advanced squamous cell carcinoma of the head and neck (in combination with radiotherapy), Soft tissue sarcoma (in combination with radiotherapy).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}